The estimated Net Worth of John M Jr Fluke is at least $358 mil dollars as of 3 February 2021. John Fluke owns over 29,003 units of Athira Pharma stock worth over $70,503 and over the last 21 years John sold ATHA stock worth over $287,400.
John has made over 4 trades of the Athira Pharma stock since 2005, according to the Form 4 filled with the SEC. Most recently John exercised 29,003 units of ATHA stock worth $35,094 on 3 February 2021.
The largest trade John's ever made was exercising 29,003 units of Athira Pharma stock on 3 February 2021 worth over $35,094. On average, John trades about 952 units every 138 days since 2003. As of 3 February 2021 John still owns at least 143,884 units of Athira Pharma stock.
You can see the complete history of John Fluke stock trades at the bottom of the page.
John's mailing address filed with the SEC is C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011.
Over the last 4 years, insiders at Athira Pharma have traded over $100,296 worth of Athira Pharma stock and bought 5,411,219 units worth $62,123,025 . The most active insiders traders include Advisors Llcperceptive Life..., Investments, Lpwong Roderic... y Joseph Edelman. On average, Athira Pharma executives and independent directors trade stock every 33 days with the average trade being worth of $62,547. The most recent stock trade was executed by Andrew Gengos on 3 September 2024, trading 1,272 units of ATHA stock currently worth $725.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Athira Pharma executives and other stock owners filed with the SEC include: